Helius Medical Technologies, Inc. Stock

Equities

HSDT

US42328V8019

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
4.5 USD +1.35% Intraday chart for Helius Medical Technologies, Inc. -12.54% -44.02%
Sales 2024 * 977K Sales 2025 * 5.72M Capitalization 3.99M
Net income 2024 * -11M Net income 2025 * -9M EV / Sales 2024 * 4.09 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.7 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-1.02 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center CI
Top Premarket Gainers MT
Helius Medical Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Helius Medical Technologies, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Helius Medical Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q4 Revenue $134,000 MT
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke CI
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller CI
Traders Await Fresh Cues After Powell's Rate-Cut Commentary, Stifling US Equity Futures Pre-Bell MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday as Earnings Flow Intensifies MT
Top Premarket Gainers MT
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients CI
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000 MT
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000 MT
More news

Latest transcript on Helius Medical Technologies, Inc.

1 day+1.35%
1 week-12.54%
Current month-22.81%
1 month-19.35%
3 months-35.71%
6 months-38.44%
Current year-44.02%
More quotes
1 week
4.42
Extreme 4.42
5.10
1 month
4.42
Extreme 4.42
7.19
Current year
4.29
Extreme 4.29
9.50
1 year
4.29
Extreme 4.29
14.44
3 years
4.29
Extreme 4.29
874.50
5 years
4.29
Extreme 4.29
5 792.51
10 years
4.29
Extreme 4.29
36 225.04
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 17-08-03
Director of Finance/CFO 63 20-06-08
Chief Tech/Sci/R&D Officer 57 21-07-07
Members of the board TitleAgeSince
Director/Board Member 85 14-11-17
Chief Executive Officer 58 17-08-03
Chairman 53 15-12-28
More insiders
Date Price Change Volume
24-04-26 4.5 +1.35% 5,124
24-04-25 4.44 -7.79% 13,586
24-04-24 4.815 -3.31% 17,231
24-04-23 4.98 -1.87% 4,077
24-04-22 5.075 -1.36% 8,376

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT

More quotes
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.5 USD
Average target price
15.47 USD
Spread / Average Target
+243.70%
Consensus